Novartis COVID-19 Trials

Novartis clinical trial efforts in COVID-19 R&D.

Content from this campaign

Research, Reports & Publications

Novartis to Sponsor Large Clinical Trial of Hydroxychloroquine in Hospitalized COVID-19 Patients
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease.
Novartis logo

More from Novartis

  1. Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
    Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...

  2. Novartis US Foundation
    Initiatives summarizing efforts from the Novartis US Foundation.

  3. Novartis COVID-19 Trials
    Novartis clinical trial efforts in COVID-19 R&D.

  4. Novartis US Foundation COVID-19 Response
    In response to the COVID-19 pandemic in the US, the Novartis US Foundation established a Response Fund, which will provide USD 5 million over a one...

  5. Novartis – science based innovation for better patient outcomes
    Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

  6. Novartis Foundation Leprosy Elimination Initiative
    The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...

  7. Novartis Access: Medicines to treat chronic diseases in lower-income countries
    Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to...

  8. The Novartis Malaria Initiative
    For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...